US biotechnology company Terremoto Biosciences has appointed Charles Baum CEO. He succeeds Peter Thompson, who will continue to serve as Terremoto’s board chairperson.

Bristol Myers Squibb (BMS) wants to invest $400 million for the construction and design of a sterile drug product (SDP) facility at its Cruiserath campus in Dublin...

Bristol Myers Squibb will acquire RayzeBio for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired. The transaction was...

Bristol Myers Squibb (BMS) and Karuna Therapeutics have entered into a definitive merger agreement under which the US drug maker has agreed to acquire the Boston-based...

Bristol-Myers Squibb (BMS) announced that it will acquire Mirati Therapeutics for up to $5.8 billion. BMS is to pay $58.00 per share in cash, for a total equity value of...

In this interview, Jinling Chen, head of WuXi STA’s drug product business, and Jamie Andrews, site head of WuXi STA’s Couvet facility, explain the company’s strategy and...

Lotte Biologics, part of South Korean conglomerate Lotte, has detailed expansions plans for the business as it embarks on a path to become a top 10 CDMO by 2030.

Bristol-Myers Squibb (BMS) is suing AstraZeneca Pharmaceuticals, alleging that the Anglo-Swedish drugmaker’ Imfinzi to treat lung and bladder cancer infringes several...